Step 1 of 2
A recent FDA approval of a drug indicated for patients with diffuse midline glioma (DMG) with a mutation in H3K27 has led to an overhaul of how this cancer is treated in pediatric and adult patients. In this clinical forum, experts will answer questions related to the program, “Implementing Systemic Therapy in H3K27-Altered DMG: Practical Strategies to Optimize Postradiation Care.” This social media forum provides learners with ongoing access to faculty throughout the certified life of this program. Learners are encouraged to submit their questions here.